These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37604681)

  • 1. HIV-1 DNA drug resistance testing to guide successful suppression of low-level viraemia: a case report.
    Cao B; Liu M; Zhu R; Yuan T; E'er A; Song S; Wang T; Zhong L
    Sex Transm Infect; 2023 Dec; 99(8):575. PubMed ID: 37604681
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
    Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
    Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
    Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.
    Vancoillie L; Mortier V; Demecheleer E; Schauvliege M; Vandekerckhove L; Vogelaers D; Verhofstede C
    Antivir Ther; 2015; 20(8):789-94. PubMed ID: 25945956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
    Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
    AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.
    Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.
    Mackie NE; Phillips AN; Kaye S; Booth C; Geretti AM
    J Infect Dis; 2010 May; 201(9):1303-7. PubMed ID: 20350161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term HIV-1 suppression in the Brazilian public health system.
    de Sa-Filho DJ; de Arruda Souza T; Golegã AA; Diaz RS; Caseiro MM
    AIDS Patient Care STDS; 2009 May; 23(5):313-4. PubMed ID: 19327023
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.
    Ryscavage P; Kelly S; Li JZ; Harrigan PR; Taiwo B
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3585-98. PubMed ID: 24733471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.
    Zaccarelli M; Lorenzini P; Tozzi V; Forbici F; Ceccherini-Silberstein F; Gori C; D'Arrigo R; Trotta MP; Narciso P; Perno CF; Antinori A;
    Infection; 2009 Jun; 37(3):203-9. PubMed ID: 19274429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.